BRCA1 and pancreatic neoplasm: Our present results suggested that repression of KLF5 promoted olaparib-induced DNA damage in pancreatic cancer cells and increased olaparib sensitivity by suppressing the transcription of BRCA1, which could be reversed by upregulation of BRCA1.